IDH1/2 mutations occur in roughly 15%-20% of AML (with IDH1 mutated in ~6%-10% and IDH2 in ~12% of patients) and are neomorphic, endowing the enzyme with a new activity [30]. Here, IDH2 is linked to acute myeloid leukemia.